Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria.
Clin Infect Dis. 1998 Sep; 27(3):494-9.CI

Abstract

Currently recommended prophylactic regimens for Plasmodium falciparum malaria are associated with a high incidence of adverse events and/or suboptimal efficacy. In a double-blind, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of atovaquone/proguanil hydrochloride (250 mg/100 mg per tablet) to eliminate preexisting infection. Immediately thereafter, subjects were randomized to one of the three prophylactic regimens to receive one atovaquone/proguanil tablet daily (n = 68), two atovaquone/proguanil tablets daily (n = 65), or placebo (n = 65) for 10 weeks. The study endpoint for any subject was the development of parasitemia, evident on blood smear, during prophylaxis. Of the evaluable subjects, all in the low-dose (54 of 54) and high-dose (54 of 54) atovaquone/proguanil groups remained malaria-free during the 10-week prophylaxis period, in contrast to only 48% (26 of 54) in the placebo group (P < .001). Both atovaquone/proguanil prophylactic regimens were as well tolerated as placebo. Thus, atovaquone/proguanil appears to be highly efficacious and safe as prophylaxis for P. falciparum malaria.

Authors+Show Affiliations

U.S. Army Medical Research Unit, Nairobi, Kenya.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

9770146

Citation

Shanks, G D., et al. "Efficacy and Safety of Atovaquone/proguanil as Suppressive Prophylaxis for Plasmodium Falciparum Malaria." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 27, no. 3, 1998, pp. 494-9.
Shanks GD, Gordon DM, Klotz FW, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis. 1998;27(3):494-9.
Shanks, G. D., Gordon, D. M., Klotz, F. W., Aleman, G. M., Oloo, A. J., Sadie, D., & Scott, T. R. (1998). Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 27(3), 494-9.
Shanks GD, et al. Efficacy and Safety of Atovaquone/proguanil as Suppressive Prophylaxis for Plasmodium Falciparum Malaria. Clin Infect Dis. 1998;27(3):494-9. PubMed PMID: 9770146.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. AU - Shanks,G D, AU - Gordon,D M, AU - Klotz,F W, AU - Aleman,G M, AU - Oloo,A J, AU - Sadie,D, AU - Scott,T R, PY - 1998/10/14/pubmed PY - 1998/10/14/medline PY - 1998/10/14/entrez SP - 494 EP - 9 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 27 IS - 3 N2 - Currently recommended prophylactic regimens for Plasmodium falciparum malaria are associated with a high incidence of adverse events and/or suboptimal efficacy. In a double-blind, placebo-controlled, randomized clinical trial in western Kenya, adult volunteers received a treatment course of atovaquone/proguanil hydrochloride (250 mg/100 mg per tablet) to eliminate preexisting infection. Immediately thereafter, subjects were randomized to one of the three prophylactic regimens to receive one atovaquone/proguanil tablet daily (n = 68), two atovaquone/proguanil tablets daily (n = 65), or placebo (n = 65) for 10 weeks. The study endpoint for any subject was the development of parasitemia, evident on blood smear, during prophylaxis. Of the evaluable subjects, all in the low-dose (54 of 54) and high-dose (54 of 54) atovaquone/proguanil groups remained malaria-free during the 10-week prophylaxis period, in contrast to only 48% (26 of 54) in the placebo group (P < .001). Both atovaquone/proguanil prophylactic regimens were as well tolerated as placebo. Thus, atovaquone/proguanil appears to be highly efficacious and safe as prophylaxis for P. falciparum malaria. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/9770146/Efficacy_and_safety_of_atovaquone/proguanil_as_suppressive_prophylaxis_for_Plasmodium_falciparum_malaria_ DB - PRIME DP - Unbound Medicine ER -